Table 2.
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation
| No. (SFN/BSC) | Duration after LT (mo) | mTOR inhibitor (yes/no) | Response rate (% complete/partial/stable) | Median OS (mo) | Time to progression (mo) |
Drug toxicity leading to |
||
| Dose reduction (% patient) | Discontinuation (% patient) | |||||||
| Meta-analysis | ||||||||
| Mancuso et al[42],2015 | 113 | 13.6 | - | 0/4.8/44.4 | 10.5 | 5.6 | 42.8 | 31.9 |
| Retrospective cohort | ||||||||
| Sposito et al[43], 2013 | 15/24 | 38.1/15.72 | 7/8 | - | 21.3/11.82 | 8.8/10.2 | 53.3 | 4.1 |
| De'Angelis et al[45], 2016 | 15/18 | 18 | 7/8 | 0/26.6/46.8 | 41.4/19.12 | - | 53.3 | 13.3 |
| Pinero et al[46], 2016 | 10/10 | - | 7/3 | - | 20/12.5 | 5/32 | 90 | 20 |
| Case series | ||||||||
| Yoon et al[47], 2010 | 13 | 12.3 | 1/12 | 0/0/46 | 5.4 | 2.9 | 30.7 | 0 |
| Kim et al[48],2010 | 9 | 12.4 | 7/2 | 11/0/44 | -1 | - | - | 0 |
| Vitale et al[49], 2012 | 10 | 7 | 10/0 | 0/20/60 | 18 | 8 | 40 | 30 |
| Gomez-Martin et al[50], 2012 | 31 | 22.6 | 31/0 | 0/3.8/50 | 19.3 | 6.77 | 25.8 | - |
| Weinmann et al[51], 2012 | 11 | 37.5 | 9/2 | 0/0/36 | 20.1 | 4.1 | 73 | 18 |
| Sotiropoulos et al[52], 2012 | 14 | 8 | 14/0 | - | 25 | - | 33 | 17 |
| Zavaglia et al[44], 2013 | 11 | 12 | 7/4 | 0/18/9 | 5 | 17 | 90 | - |
1
Median survival not reached;
2
Statistically significant. SFN: Sorafenib; BSC: Best supportive care; LT: Liver transplant; mTOR: Mammalian target of rapamycin; OS: Overall survival.